Acinetobacter baumannii is a ubiquitous pathogen that has emerged as a major cause of healthcare-associated infections at Ladoke Akintola University Teaching Hospital. Isolates were assayed according to standard protocol. The isolates were subjected to molecular techniques to detect blaOXA, blaTEM, blaCTX-M, and blaSHV genes in strains of the A. baumannii isolates.
The prevalence of A. baumannii was 8.5% and was most prevalent among patients in the age group 51–60 (36%); the male patients (63.6%) were more infected than their female counterparts. Patients (72.7%) in the intensive care unit (ICU) were most infected with this organism. The isolates showed 100% resistance to both amikacin and ciprofloxacin and 90.9% to both ceftriaxone and ceftazidime, while resistance to the other antibiotics used in this study were: piperacillin (81.8%), imipenem (72.7%), gentamycin (72.2%), and meropenem (63.6%). None of the isolates was, however, resistant to colistin. PCR results showed that blaOXA, blaTEM, and blaCTX-M genes were positive in some isolates, while blaSHV was not detected in any of the isolates.
This study has revealed that the strains of A. baumannii isolated are multiple drug resistant. Regular monitoring, judicious prescription, and early detection of resistance to these antibiotics are, therefore, necessary to check further dissemination of the organism.
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Bergogne-Berezin E , Towner KJ: Acinetobacter spp. as nosocomial pathogen: microbiological, clinical and epidemiological features. Clin Microbiol Rev 148–65 (1996)
-
2.
Zarrilli R , Crispino M, Bagattini M, Barretta E, Di Popolo A, Triassi M, Villari P: Molecular epidemiology of sequential outbreaks of Acinetobacter baumannii in an intensive care unit shows the emergence of carbapenem resistance. J Clin Microbiol 42, 946–953 (2004)
-
3.
Michele I , Laura V, Daniela F, Roberta B, Francesco I, Raoul JPB: et al.: Whole genome pyrosequencing of an epidemic multidrug – resistant A. baumannii strain belonging to the European clone II group. Antimicrob Agents Chemother 25, 2616–2625 (2008)
-
4.
Rosenthal S , Tager IB: Prevalence of gram negative rods in the normal pharyngeal flora. Ann Intern Med 83, 355–357 (1975)
-
5.
Montefour K , Frieden J, Hurst S, Helmich C, Headley D, Martin M, Boyle DA: Acinetibacter baumannii. An emerging multidrug resistant pathogen in critical care. Critical Care Nurse 28, 15–25 (2008)
-
6.
Seifert H , Richter W, Pulverer G: Clinical and bacteriological features of relapsing shunt-associated meningitis due to Acinetibacter baumannii. Eur, J Clin Microbiol Infect Dis 14, 130–134 (1995)
-
7.
Peleg AY , Seifert H, Paterson DL: Acinetobacter baumannii: Emerging of a successful pathogen. Clin Microbiol Rev 21, 538–582 (2008)
-
8.
Surasarang K , Narksawat K, Danchaivijitri, Siripanichgon K, Sujirarat G, Rongrungrueng Y, Kiratisin P.: Risk factors for multidrug resistant Acinetobacter baumannii nosocomial infection. J Med Assoc Thailand 90, 1633–1639 (2007)
-
9.
Ling M L , Ang A, Wee M, Wang GC: A nosocomial outbreak of multiresistant Acinetobacter baumannii originating from an intensive care unit. Infect Control Hosp Epidemiol 22, 48–49 (2001)
-
10.
Clinical and Laboratory Standards Institute (2011): Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA
-
11.
Olowe OA , Choudhary S, Schierack P, Wieler LH, Makanjuola OB, Olayemi AB, Anjum M: Pathotyping blaCTX-M Escherichia coli from Nigeria. Eur, J Microbiol Immunol 3(2), 120–125 (2013)
-
12.
Dijkshoorn L , Nemec A, Seifert H: An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol 5(12), 939–951 (2007)
-
13.
Siau H , Yuen KY, Wong SSY: The epidemiology of Acinetobacter infections in Hongkong, J Med Microbiol 44, 340–347 (1996)
-
14.
Nabil K , Bjørg H, Kristin H, Gunnar SS, Arnfinn S, Ørjan S: Species identification and molecular characterization of Acinetobacter spp. blood culture isolates from Norway. J Antimicrob Chemother 10, 1093 (2001)
-
15.
Namita J , Pushpa S, Lalit S: Acinetobacter baumannii isolates in a tertiary care hospital: antimicrobial resistance and clinical significance. J Clin Microbiol Infect 2(2), 57–63 (2012)
-
16.
Poutanen SM , Louie M, Simor AE: Risk factors, clinical features and outcome of Acinetobacter bacteremia in adults. Eur, J Clin Microbiol Infect Dis 16(10), 737–740 (1997)
-
17.
Mera RM , Miller LA, Amrine-Madsen H, Sahm DF.: Acinetobacter baumannii 2002–2008: increase of carbapenem-associated multiclass resistance in the United States. Microb Drug Resist 16(3), 209–215 (2010)
-
18.
Prashanth K , Badrinath S: Nosocomial infections due to Acinetobacter species: clinical findings, risk and prognostic factors. Indian, J Med Microbiol 24, 39–44 (2006)
-
19.
Qin XP , Wang LY, Xu WJ: Acinetobacter baumannii infection in children and hospital infection control. Chin, J Nosocomiol 19, 1305–1307 (2009)
-
20.
Dent LL , Marshall DR, Pratap S, Hulette RB: Multidrug resistant Acinetobacter baumannii: a descriptive study in a city hospital. BMC Infect Dis 7, 196 (2010)
-
21.
Baran G , Erbay A, Bodur H, Ongürü P, Akinci E, Balaban N, Cevik MA: Risk factors for nosocomial imipenem resistant Acinetobacter baumannii infections. Int, J Infect Dis 12, 16–20 (2008)
-
22.
Wang SH , Sheng WH, Chang YY, Wang LH, Lin HC, Chen ML, Pan HJ, Ko WJ, Chang SC, Lin FY: Healthcare-associated outbreak due to pan-drug resistant Acinetobacter baumanii in a surgical intensive care unit, J Hosp Infect 53, 97–102 (2003)
-
23.
Farahani KR , Moniri R, Shajari GH et al.: Antibiotic resistance patterns and the spread of antibiotic resistance genes in Acinetobacter species isolated from Kashan, Feyz, Kashan University of Medical Sci Health Serv 12(4), 60–66 (2009)
-
24.
Nseir S DI Pompeo C , Cavestri B, Jozefowicz E, Nyunga M, Soubrier S, Roussel-Delvallez M, Saulnier F, Mathieu D, Durocher A: Multiple-drug resistant bacteria in patients with severe acute exacerbation of chronic obstructive pulmonary disease: prevalence, risk factors, and outcome. Crit Care Med 34, 2959–2966 (2006)
-
25.
Gaur A , Garg A, Prakash P, Anupurba S, Mohapatra TM: Observations on carbapenem resistance by minimum inhibitory concentration in nosocomial isolates of Acinetobacter species: an experience at a tertiary care hospital in North India. J Health Popul Nutr 26, 183–188 (2008)
Monthly Content Usage
| Abstract Views | Full Text Views | PDF Downloads | |
|---|---|---|---|
| Aug 2020 | 0 | 2 | 3 |
| Sep 2020 | 0 | 5 | 2 |
| Oct 2020 | 0 | 12 | 21 |
| Nov 2020 | 0 | 4 | 5 |
| Dec 2020 | 0 | 3 | 7 |
| Jan 2021 | 0 | 1 | 2 |
| Feb 2021 | 0 | 0 | 0 |
Copyright Akadémiai Kiadó
AKJournals is the trademark of Akadémiai Kiadó's journal publishing business branch.
Copyright Akadémiai Kiadó AKJournals is the trademark of Akadémiai Kiadó's journal publishing business branch.
Powered by PubFactory